- Home
- MSN vs LPTX Comparison
MSN vs LPTX Comparison
Compare MSN & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSN
- LPTX
- Stock Information
- Founded
- MSN 1948
- LPTX 2011
- Country
- MSN United States
- LPTX United States
- Employees
- MSN N/A
- LPTX N/A
- Industry
- MSN Consumer Electronics/Appliances
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MSN Consumer Staples
- LPTX Health Care
- Exchange
- MSN Nasdaq
- LPTX Nasdaq
- Market Cap
- MSN 9.3M
- LPTX 11.1M
- IPO Year
- MSN 1994
- LPTX N/A
- Fundamental
- Price
- MSN $0.42
- LPTX $0.29
- Analyst Decision
- MSN
- LPTX Hold
- Analyst Count
- MSN 0
- LPTX 1
- Target Price
- MSN N/A
- LPTX N/A
- AVG Volume (30 Days)
- MSN 344.5K
- LPTX 2.3M
- Earning Date
- MSN 08-14-2025
- LPTX 08-14-2025
- Dividend Yield
- MSN N/A
- LPTX N/A
- EPS Growth
- MSN N/A
- LPTX N/A
- EPS
- MSN N/A
- LPTX N/A
- Revenue
- MSN $10,262,000.00
- LPTX N/A
- Revenue This Year
- MSN N/A
- LPTX N/A
- Revenue Next Year
- MSN N/A
- LPTX N/A
- P/E Ratio
- MSN N/A
- LPTX N/A
- Revenue Growth
- MSN 8.49
- LPTX N/A
- 52 Week Low
- MSN $0.28
- LPTX $0.22
- 52 Week High
- MSN $0.59
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- MSN 45.38
- LPTX 47.26
- Support Level
- MSN $0.32
- LPTX $0.28
- Resistance Level
- MSN $0.44
- LPTX $0.31
- Average True Range (ATR)
- MSN 0.05
- LPTX 0.04
- MACD
- MSN -0.01
- LPTX 0.00
- Stochastic Oscillator
- MSN 34.78
- LPTX 42.52
About MSN Emerson Radio Corporation
Emerson Radio Corp operates in the consumer electronics industry. The company designs, sources, imports, and markets a variety of houseware and consumer electronic products, and licenses the Emerson trademark domestically and internationally. The products offered by the company are televisions, digital versatile disc players and video cassette recorders, audio accessories, microwave ovens, home theatres, high-end audio products, office products, mobile stereo, and wireless products.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.